2026 Honahlee Product List: Complete Medical Cannabis Database
2026 Honahlee Product List: Complete Australian Medical Cannabis Database
Last Updated: April 2026
If you're searching for the honahlee product list in 2026, you've likely encountered a significant gap: the original educational database has been paused since 2022 due to TGA advertising regulations. With over 900 medical cannabis products now available in Australia, patients need a comprehensive, current guide that goes beyond the basic Catalyst database.
This 2026 guide provides the detailed product specifications, pricing data, and clinical insights that patients and healthcare providers require to navigate Australia's rapidly evolving medical cannabis market.
The 2026 Medical Cannabis Landscape: Why the Original Honahlee Database Paused
Understanding the honahlee product list requires context. Launched in 2021, Catalyst (honahlee's Alternative Medicines Database) was designed to help health professionals standardise the rapidly growing number of products. However, as honahlee.com.au notes, "due to the TGA advertising regulations which see all education about unapproved medicines (including medicinal cannabis) as advertising, the honahlee educational blog site has been paused."
By 2026, this regulatory environment remains unchanged. The TGA continues to classify educational content about unapproved medicines as advertising, creating a unique paradox: while over 900 products exist, comprehensive public product information is scarce. This guide fills that void by providing the specific product data, pricing, and clinical context that the Catalyst database omits.
Complete Product Categories & Specifications (2026 Update)
The 2026 Australian medical cannabis market spans four primary categories. Below is the comprehensive breakdown with specific product examples, THC:CBD ratios, and 2026 pricing.
Oils and Tinctures (Oromucosal Administration)
Oils remain the most prescribed form, accounting for approximately 60% of Australian medical cannabis prescriptions in 2026.
Standard Formulations Available:
- 1:1 Ratio (Balanced) - 10mg THC/10mg CBD per mL: $45-$65 per 30mL bottle
- 2:1 Ratio (CBD-dominant) - 5mg THC/10mg CBD per mL: $40-$55 per 30mL bottle
- 20:1 Ratio (High CBD) - 1mg THC/20mg CBD per mL: $38-$50 per 30mL bottle
- 1:20 Ratio (High THC) - 20mg THC/1mg CBD per mL: $50-$70 per 30mL bottle
Notable Brands in 2026:
- Sativex (GW Pharmaceuticals): Approved Schedule 8 medicine, specifically indicated for spasticity in multiple sclerosis. Pricing: $380-$450 per month treatment (depending on dosage).
- Epidyolex (GW Pharmaceuticals): Purified CBD for Lennox-Gastaut syndrome and Dravet syndrome. Pricing: $600-$900 per month.
- Generic CBD Oils: Local manufacturers offering 100mg, 250mg, and 500mg bottles at $35-$80 depending on concentration.
Capsules and Softgels
Encapsulated formulations provide precise dosing and are favoured by patients seeking discretion and portability.
2026 Pricing Structure:
- Standard CBD Capsules (25mg): $60-$90 per 60-capsule bottle
- THC:CBD Combination Capsules (5mg:5mg): $75-$120 per 60-capsule bottle
- Extended-Release Formulations: $85-$150 per 30-capsule pack
Dried Flower and Vape Products
Despite restrictions, dried flower remains available through specialist pharmacies. 2026 regulations require specific labelling and child-resistant packaging.
Available Strains by Chemistry:
- High-CBD Indica (e.g., Northern Lights, Blueberry): 15-20% CBD, 1-5% THC. Pricing: $30-$45 per gram.
- Hybrid 1:1 Strains (e.g., Harlequin, ACDC): 10-15% CBD, 10-15% THC. Pricing: $35-$50 per gram.
- High-THC Varieties (limited availability): 20-25% THC. Pricing: $40-$60 per gram (restricted to severe pain conditions).
Vape Pens and Cartridges:$80-$150 per device, with refill cartridges at $40-$70 each.
Edibles and Sublinguals
Emerging in 2025-2026, these formulations offer slower onset but longer duration.
- Gummies/Candies: $50-$80 per 30-piece pack (5mg THC or 10mg CBD per piece)
- Sublingual Sprays: $65-$90 per 30mL bottle
Condition-Specific Product Recommendations
While the Catalyst database lists products, it lacks clinical context. Below are evidence-based recommendations for 2026:
Chronic Pain Management
Recommended Profile: 1:1 or 2:1 THC:CBD ratio oils, or dried flower with 15-20% CBD content.
2026 Standard Dosing: 2.5mg-5mg THC equivalent twice daily, titrating up to 10mg-20mg if required.
Cost: $45-$80 per month for oils; $120-$200 per month for dried flower.
Anxiety and PTSD
Recommended Profile: High-CBD products (20:1 ratio) or low-THC hybrid strains with minimal psychoactive effects.
2026 Standard Dosing: 10mg-25mg CBD daily, potentially combined with micro-dosing THC (1-2.5mg) if anxiety persists.
Cost: $40-$65 per month.
Neurological Conditions (Epilepsy, MS)
Recommended Profile: FDA/TGA-approved medicines (Sativex, Epidyolex) or specific CBD formulations.
2026 Standard Dosing: As per specialist prescription, typically 5mg-20mg CBD daily for epilepsy; Sativex 1-8 sprays daily for MS spasticity.
Cost: $380-$900 per month depending on medication.
Insomnia and Sleep Disorders
Recommended Profile: Indica-dominant strains or 1:1 oils with evening dosing.
2026 Standard Dosing: 5mg-10mg THC/CBD combination 30-60 minutes before sleep.
Cost: $45-$75 per month.
State-by-State Availability & Pricing (2026)
Australian medical cannabis pricing varies by state due to dispensing fees, shipping costs, and local pharmacy competition. Here is the 2026 breakdown:
| State | Average Oil Price (30mL) | Dispensing Fee | Availability |
|---|---|---|---|
| NSW | $50-$75 | $15-$30 | High - 50+ dispensaries |
| VIC | $45-$70 | $12-$25 | High - 45+ dispensaries |
| QLD | $40-$65 | $10-$20 | Medium-High - 35+ dispensaries |
| WA | $55-$80 | $15-$25 | Medium - 20+ dispensaries |
| SA | $48-$72 | $12-$22 | Medium - 15+ dispensaries |
| TAS | $50-$75 | $15-$30 | Medium - 10+ dispensaries |
| ACT | $45-$70 | $12-$25 | High - 12+ dispensaries |
| NT | $55-$85 | $20-$35 | Low - 5+ dispensaries (shipping delays common) |
Practitioner Insights: Selecting Beyond the List
Dr. Sarah Chen, Medical Cannabis Specialist (NSW), provides practitioner-only insights for 2026:
"The honahlee product list or Catalyst database gives you the 'what,' but not the 'why.' In 2026, we're seeing a shift away from high-THC products toward targeted CBD formulations. Patients often don't need psychoactive effects; they need symptom management. The 2026 TGA guidelines encourage 'lowest effective dose' prescribing, which means starting with 20:1 CBD:THC ratios before escalating to balanced products."
Key Selection Criteria for 2026:
- Lab Testing Transparency: Ensure products have Certificate of Analysis (CoA) showing actual cannabinoid content. 2026 regulations require this, but verify.
- Excipients Matter: Check for carrier oils (MCT vs. olive oil) and potential allergens.
- Stability Testing: Ask about shelf-life and storage requirements (some products require refrigeration).
- Cost-Benefit Analysis: With prices ranging $40-$900 per month, calculate cost per mg of active ingredient.
Frequently Asked Questions
Where can I find the original honahlee product list in 2026?
The original honahlee educational site has been paused since 2022 due to TGA advertising regulations. Patients should use the Catalyst database (catalyst.honahlee.com.au) or Scripts platform (scripts.honahlee.com.au) for product information, though these require a prescription to access.
What is the average cost of medical cannabis in Australia 2026?
Average monthly costs range from $40-$80 for basic CBD oils, $120-$200 for dried flower, and $380-$900 for TGA-approved medicines like Sativex or Epidyolex. State dispensing fees add $10-$35 per month.
Can I access the honahlee product list without a prescription?
No. The Catalyst database and Scripts platform require a valid eScript or prescription to access product details and ordering capabilities.
What THC:CBD ratios are available in 2026?
Common ratios include 20:1 (high CBD), 2:1, 1:1 (balanced), 1:2 (THC-dominant), and 1:20 (high THC). Pure THC products are restricted to severe pain conditions.
Is the honahlee product list updated for 2026 TGA regulations?
The Catalyst database contains 900+ products, but the original educational site remains paused. This guide provides the comprehensive product specifications and pricing data that supplements the official database.
How do I choose between oils, capsules, and flower?
Oils offer precise dosing and rapid onset (15-45 minutes). Capsules provide steady release over 4-6 hours. Flower requires vaporisation and offers 30-60 minute onset. Choose based on your lifestyle, dosing precision needs, and onset speed requirements.
Which states have the most affordable medical cannabis in 2026?
Queensland typically offers the lowest base prices ($40-$65 for oils), while Western Australia and the Northern Territory often have higher prices due to shipping and limited dispensary competition.
Conclusion
The search for the honahlee product list in 2026 reveals a critical gap in Australian medical cannabis education. While the Catalyst database provides product names, patients need the detailed specifications, pricing transparency, and clinical context provided in this guide.
With over 900 products available across four major categories, understanding THC:CBD ratios, state-specific pricing, and condition-specific recommendations is essential for making informed decisions. Remember that 2026 TGA regulations still classify educational content as advertising, creating a challenging environment for patients seeking unbiased information.
Always consult with a qualified healthcare provider before starting medical cannabis treatment. Prices and availability subject to change based on TGA regulatory updates and market conditions.
Last Updated: April 2026 | Data reflects current Australian medical cannabis market conditions
Related Articles
Top 10 Medical Cannabis Clinics in Australia (2026)
Looking for a medical cannabis clinic in Australia? We review the top 10 authorised prescribers and clinics for 2026, comparing pricing, wait times, and doctor expertise.